Those nice people from the National Institute for Health and Clinical Excellence (NICE) have issued new guidelines to doctors in the UK recommending they make greater use of Acomplia. NICE has the responsibility of leading the fight against obesity. It has adopted a national policy that urgent action is needed, but there are only a few treatments considered suitable for patients. (more…)

Whatever you read about acomplia and weight loss, there is one constant. Acomplia on its own cannot reduce your weight. It is designed to work alongside a low-calorie diet and physical exercise. So what kind of activity should people adopt? (more…)

I am always impressed by a well-rounded acronym. It shows the research team is delighted by both science and language. In this case, we have the cumbersome An International Study of Rimonabant in Dyslipidemia with Atherogenic Risk in Abdominally Obese Patients distilled into the more convenient ADAGIO-LIPIDS. It is a shame that the team felt they had to cheat — I suppose AISRIDARAOP is not quite so catchy. Perhaps it works better in French. Two new reports based on the clinical trial of acomplia (generic name rimonabant) were presented on the 29th April in Istanbul at the 77th European Atherosclerosis Society Congress. (more…)

  This April has been good news month in Philadelphia. According to a report published in Pediatrics, a research project to tackle obesity among children has been a success. Ten elementary schools were chosen, five instituted the weight loss program (although more local schools later began the program informally). Essentially, the proactive schools attacked the problem from three sides: through changing the food served in the cafeteria and sold through vending machines, by reintroducing physical exercise, and by teaching better lifestyles to both the children and their parents. (more…)

History is a strange beast. You can only see it when you turn and look back. The closer it is to you, the less easy it is to see. The difficulty with writing about acomplia is that you must always start somewhere. Wherever you pick in time, the real question is how far back to look. What have we taken for granted? What gaps have we left? So in this article, we catch up with the past. Just to make sure that we have everyone on the same virtual page. (more…)

  The pharmaceutical company, Sanofi-Aventis, has always promoted acomplia as achieving the best results when combined with a low-calorie diet and exercise. There is a simple explanation for this. People who are sufficiently motivated will lose weight if they reduce their calorie intake below their normal daily requirement and increase their metabolic rate through exercise. This forces the body to burn fat as stored energy to fill the gap. So why take acomplia? In the clinical trials, many of the people on placebo also lost weight. (more…)

At the meeting of the American College of Cardiology held in Chicago this March, Merck & Co released some clinical data from the Phase III trials for their proposed competitor to acomplia (rimonabant). This new medication, still going by its generic name of taranabant, targets the same cannabinoid system as acomplia. It is therefore interesting to compare results since, if it gains regulatory approval, it will be a direct competitor to acomplia. (more…)

  Science is one of those endlessly fascinating games that people play with ideas. The method could not be easier to state. You propose a hypothesis and design an experiment to collect evidence to test whether your hypothesis is true (I always pay particular attention when anyone starts talking about truth — if ever there was a flexible friend, truth would be it). So, now your results are in. You claim definitive evidence that “proves” what you speculated was either true or not true. Now it is up to the rest of the world to see whether it can replicate your findings. The more independent people who can reproduce the same results, the more likely it is that your hypothesis is true or not true. (more…)

  The bad news on obesity in the United States continues to roll in with about one third of adult Americans now considered obese. Against this continuous drip feed of research data showing the scale of the emerging medical crisis, it is all the more strange that the Food and Drug Administration continues to resist approving medications such as Acomplia. It would be easy to understand this reluctance if there were already three or four major medications on the market that would help to combat the epidemic spread of obesity. But this is not the case. (more…)

  In November, 2007 the British Medical Journal published a new piece of meta-research into the relative effectiveness of Orlistat, Meridia and Acomplia. The difficulty with conventional research is that each individual study usually only involves a few hundred volunteers. Although these studies have to be “statistically significant”, i.e. it must be reasonable to scale up the results so that they will offer a reasonable chance of being replicated in the community at large, one study cannot be anything more than an indicator. To get the best results, you need to take a number of published clinical trials and reanalyse the data to determine whether there are trends. This is what a meta-researcher does. (more…)